Cite
Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: Is there a real benefit?
MLA
Canet, Jim, et al. “Second- or Third-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukemia in General Population: Is There a Real Benefit?” Cancer Medicine, vol. 10, no. 20, Oct. 2021, pp. 6959–70. EBSCOhost, https://doi.org/10.1002/cam4.4186.
APA
Canet, J., Cony-Makhoul, P., Orazio, S., Cornet, E., Troussard, X., Maynadié, M., Étienne, G., & Monnereau, A. (2021). Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: Is there a real benefit? Cancer Medicine, 10(20), 6959–6970. https://doi.org/10.1002/cam4.4186
Chicago
Canet, Jim, Pascale Cony-Makhoul, Sébastien Orazio, Edouard Cornet, Xavier Troussard, Marc Maynadié, Gabriel Étienne, and Alain Monnereau. 2021. “Second- or Third-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukemia in General Population: Is There a Real Benefit?” Cancer Medicine 10 (20): 6959–70. doi:10.1002/cam4.4186.